Polaris Partners

Kudos to Dyno Therapeutics on the new strategic partnership with Roche.

Yesterday we announced pricing of our Initial Public Offering. Read our full press release here: https://lnkd.in/gABqw56k

We’re excited to announce the US Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, our internally discovered #KIF18A inhibitor for the treatment of #patients with platinum-resistant high-grade serous #ovariancancer (HGSOC). This designation further underscores the potential of KIF18A inhibition to address the high unmet need in treating HGSOC and takes us one step closer to delivering new treatment options to patients. Read more about the news: https://lnkd.in/gBNtYTPW

Enjoyed speaking with Andrew Dunn to announce NOETIK $40M Series A led by Polaris Partners, Amy Schulman. The NOETIK team has made incredible progress in less than 2-years building a complex data platform and unique AI capabilities. We’re now ready to direct these capabilities toward therapeutics. Let’s go team!

Kudos to Jnana Therapeutics! The company has signed an agreement to be acquired by Otsuka Pharmaceutical Co.

📣 We’re excited to announce the release of our Alzheimer’s disease PremiOM dataset! Access to this new dataset, with its breadth of health information and deep understanding of the patient journeys, allows clinicians and researchers to track at-risk patients for earlier intervention to improve outcomes and quality of life. 📍 Read the full press release: https://hubs.ly/Q02JmQDD0 #AlzheimersDisease #Neuro #RWE #ClinicalResearch

Tectonic Therapeutic, Inc. has received IND clearance for its lead program, TX45, which is being evaluated in patients with pulmonary hypertension secondary to left heart failure with preserved ejection fraction (PH-HFpEF).

#65LAB has awarded its inaugural grant to Associate Professor Lena Ho from Duke-NUS Medical School to further her team's research in developing first-in-class therapeutics for chronic inflammation. Learn more about this milestone here: https://lnkd.in/ghyRNnTF

Congratulations to Morphic Therapeutic on this exciting milestone. The company has signed a definitive agreement to be acquired by Eli Lilly. Bravo!